REFERENCES
1. Meyts, I., Bucciol, G., Quinti, I., Neven, B., Fischer, A., Seoane,
E., Lopez-Granados, E., Gianelli, C., Robles-Marhuenda, A., Jeandel,
P.Y., et al. (2021). Coronavirus disease 2019 in patients with inborn
errors of immunity: An international study. J Allergy Clin Immunol147 , 520-531. 10.1016/j.jaci.2020.09.010.
2. Karakoc Aydiner, E., Bilgic Eltan, S., Babayeva, R., Aydiner, O.,
Kepenekli, E., Kolukisa, B., Sefer, A.P., Yalcin Gungoren, E.,
Karabiber, E., Yucel, E.O., et al. (2022). Adverse COVID-19 outcomes in
immune deficiencies: Inequality exists between subclasses. Allergy77 , 282-295. 10.1111/all.15025.
3. Chou, J., Platt, C.D., Habiballah, S., Nguyen, A.A., Elkins, M.,
Weeks, S., Peters, Z., Day-Lewis, M., Novak, T., Armant, M., et al.
(2021). Mechanisms underlying genetic susceptibility to multisystem
inflammatory syndrome in children (MIS-C). J Allergy Clin Immunol148 , 732-738 e731. 10.1016/j.jaci.2021.06.024.
4. Brown, L.K., Moran, E., Goodman, A., Baxendale, H., Bermingham, W.,
Buckland, M., AbdulKhaliq, I., Jarvis, H., Hunter, M., Karanam, S., et
al. (2022). Treatment of chronic or relapsing COVID-19 in
immunodeficiency. J Allergy Clin Immunol 149 , 557-561 e551.
10.1016/j.jaci.2021.10.031.
5. Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.H.,
Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Beziat, V., et al.
(2020). Autoantibodies against type I IFNs in patients with
life-threatening COVID-19. Science 370 . 10.1126/science.abd4585.
6. Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen,
J., Ogishi, M., Sabli, I.K.D., Hodeib, S., Korol, C., et al. (2020).
Inborn errors of type I IFN immunity in patients with life-threatening
COVID-19. Science 370 . 10.1126/science.abd4570.
7. McMenamin, M.E., Nealon, J., Lin, Y., Wong, J.Y., Cheung, J.K., Lau,
E.H.Y., Wu, P., Leung, G.M., and Cowling, B.J. (2022). Vaccine
effectiveness of two and three doses of BNT162b2 and CoronaVac against
COVID-19 in Hong Kong. medRxiv. 10.1101/2022.03.22.22272769.
8. Jara, A., Undurraga, E.A., Gonzalez, C., Paredes, F., Fontecilla, T.,
Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., et al. (2021).
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J
Med 385 , 875-884. 10.1056/NEJMoa2107715.
9. Amodio, D., Ruggiero, A., Sgrulletti, M., Pighi, C., Cotugno, N.,
Medri, C., Morrocchi, E., Colagrossi, L., Russo, C., Zaffina, S., et al.
(2021). Humoral and Cellular Response Following Vaccination With the
BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary
Immunodeficiencies. Front Immunol 12 , 727850.
10.3389/fimmu.2021.727850.
10. Delmonte, O.M., Bergerson, J.R.E., Burbelo, P.D., Durkee-Shock,
J.R., Dobbs, K., Bosticardo, M., Keller, M.D., McDermott, D.H., Rao,
V.K., Dimitrova, D., et al. (2021). Antibody responses to the SARS-CoV-2
vaccine in individuals with various inborn errors of immunity. J Allergy
Clin Immunol 148 , 1192-1197. 10.1016/j.jaci.2021.08.016.
11. Hagin, D., Freund, T., Navon, M., Halperin, T., Adir, D., Marom, R.,
Levi, I., Benor, S., Alcalay, Y., and Freund, N.T. (2021).
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with
inborn errors of immunity. J Allergy Clin Immunol 148 , 739-749.
10.1016/j.jaci.2021.05.029.
12. van Leeuwen, L.P.M., GeurtsvanKessel, C.H., Ellerbroek, P.M., de
Bree, G.J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F.,
van Gorp, E.C.M., de Wilt, F., et al. (2022). Immunogenicity of the
mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of
immunity. J Allergy Clin Immunol. 10.1016/j.jaci.2022.04.002.
13. Pham, M.N., Murugesan, K., Banaei, N., Pinsky, B.A., Tang, M.,
Hoyte, E., Lewis, D.B., and Gernez, Y. (2022). Immunogenicity and
tolerability of COVID-19 messenger RNA vaccines in primary
immunodeficiency patients with functional B-cell defects. J Allergy Clin
Immunol 149 , 907-911 e903. 10.1016/j.jaci.2021.11.022.
14. Fernandez Salinas, A., Piano Mortari, E., Terreri, S., Milito, C.,
Zaffina, S., Perno, C.F., Locatelli, F., Quinti, I., and Carsetti, R.
(2022). Impaired memory B-cell response to the Pfizer-BioNTech COVID-19
vaccine in patients with common variable immunodeficiency. J Allergy
Clin Immunol 149 , 76-77. 10.1016/j.jaci.2021.08.031.
15. Rosa Duque, J., Wang, X., Leung, D., Cheng, S., Cohen, C., Mu, X.,
Hachim, A., Zhang, Y., Chan, S.-M., Chaothai, S., et al. (2022).
Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated
vaccines in healthy adolescents (Accepted). Nat Commun.
10.21203/rs.3.rs-1327020/v1.
16. Cohen, C.A., Li, A.P.Y., Hachim, A., Hui, D.S.C., Kwan, M.Y.W.,
Tsang, O.T.Y., Chiu, S.S., Chan, W.H., Yau, Y.S., Kavian, N., et al.
(2021). SARS-CoV-2 specific T cell responses are lower in children and
increase with age and time after infection. Nat Commun 12 , 4678.
10.1038/s41467-021-24938-4.
17. Chou, J., Thomas, P.G., and Randolph, A.G. (2022). Immunology of
SARS-CoV-2 infection in children. Nat Immunol 23 , 177-185.
10.1038/s41590-021-01123-9.
18. Centre for Health Protection, Hong Kong. Recommendation for
additional dose(s) of COVID-19 vaccination. (2022).
19. Egunsola, O., Clement, F., Taplin, J., Mastikhina, L., Li, J.W.,
Lorenzetti, D.L., Dowsett, L.E., and Noseworthy, T. (2021).
Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular
Influenza Vaccines: A Systematic Review and Meta-analysis. JAMA Netw
Open 4 , e2035693. 10.1001/jamanetworkopen.2020.35693.
20. Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T.,
Tegally, H., San, J.E., Cromer, D., Scheepers, C., Amoako, D.G., et al.
(2022). Omicron extensively but incompletely escapes Pfizer BNT162b2
neutralization. Nature 602 , 654-656. 10.1038/s41586-021-04387-1.
21. Cheng, S.M.S., Mok, C.K.P., Leung, Y.W.Y., Ng, S.S., Chan, K.C.K.,
Ko, F.W., Chen, C., Yiu, K., Lam, B.H.S., Lau, E.H.Y., et al. (2022).
Neutralizing antibodies against the SARS-CoV-2 Omicron variant following
homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med.
10.1038/s41591-022-01704-7.
22. Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N.,
Bloom, N.I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022).
SARS-CoV-2 vaccination induces immunological T cell memory able to
cross-recognize variants from Alpha to Omicron. Cell 185 , 847-859
e811. 10.1016/j.cell.2022.01.015.
23. Ma, A.L.-T., Leung, D., Chan, E.Y.-H., Chim, S., Cheng, S., Ho,
F.T.-W., Lai, W.-M., Tong, P.-C., Lee, M.H.-L., Wong, W.H.-S., et al.
(2022). Antibody responses to 2 doses of mRNA COVID-19 vaccine in
pediatric patients with kidney diseases. Kidney International101 , 1069-1072.
24. Leung, D., Cohen, C.A., Mu, X., Rosa Duque, J., Cheng, S.M., Wang,
X., Wang, M., Zhang, W., Zhang, Y., Tam, I.Y., et al. (2022).
Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third
Dose of Inactivated COVID-19 Vaccine in Healthy Adolescents. SSRN: Cell
Press Sneak Peek. https://ssrn.com/abstract=4115862.
25. Perera, R.A., Mok, C.K., Tsang, O.T., Lv, H., Ko, R.L., Wu, N.C.,
Yuan, M., Leung, W.S., Chan, J.M., Chik, T.S., et al. (2020).
Serological assays for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), March 2020. Euro Surveill 25 .
10.2807/1560-7917.ES.2020.25.16.2000421.
26. Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D.,
Gilbert, P.B., Siber, G.R., Dull, P., and Plotkin, S.A. (2021). Evidence
for antibody as a protective correlate for COVID-19 vaccines. Vaccine39 , 4423-4428. 10.1016/j.vaccine.2021.05.063.
27. Shields, A.M., Faustini, S.E., Hill, H.J., Al-Taei, S., Tanner1, C.,
Ashford, F., Workman, S., Moreira, F., Verma, N., Wagg, H., et al.
(2022). Increased Seroprevalence and Improved Antibody Responses
Following Third Primary SARS-CoV-2 Immunisation: An Update From the
COV-AD Study. Front Immunol 13 . 10.3389/fimmu.2022.912571.
28. Vardhana, S., Baldo, L., II, W.G.M., and Wherry, E.J. (2022).
Understanding T cell responses to COVID-19 is essential for informing
public health strategies. Sci Immunol 7 , eabo1303.
29. Burnet, F.M. (1968). Measles as an index of immunological function.
Lancet 292 , 610-613.
https://doi-org.eproxy.lib.hku.hk/10.1016/S0140-6736(68)90701-0.
30. Okada, S., Asano, T., Moriya, K., Boisson-Dupuis, S., Kobayashi, M.,
Casanova, J.L., and Puel, A. (2020). Human STAT1 Gain-of-Function
Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I
Interferonopathy. J Clin Immunol 40 , 1065-1081.
10.1007/s10875-020-00847-x.
31. Medeiros-Ribeiro, A.C., Aikawa, N.E., Saad, C.G.S., Yuki, E.F.N.,
Pedrosa, T., Fusco, S.R.G., Rojo, P.T., Pereira, R.M.R., Shinjo, S.K.,
Andrade, D.C.O., et al. (2021). Immunogenicity and safety of the
CoronaVac inactivated vaccine in patients with autoimmune rheumatic
diseases: a phase 4 trial. Nat Med 27 , 1744-1751.
10.1038/s41591-021-01469-5.
32. Balcells, M.E., Le Corre, N., Duran, J., Ceballos, M.E., Vizcaya,
C., Mondaca, S., Dib, M., Rabagliati, R., Sarmiento, M., Burgos, P.I.,
et al. (2022). Reduced immune response to inactivated SARS-CoV-2 vaccine
in a cohort of immunocompromised patients in Chile. Clin Infect Dis.
10.1093/cid/ciac167.
33. Aikawa, N.E., Kupa, L.V.K., Pasoto, S.G., Medeiros-Ribeiro, A.C.,
Yuki, E.F.N., Saad, C.G.S., Pedrosa, T., Fuller, R., Shinjo, S.K.,
Sampaio-Barros, P.D., et al. (2022). Immunogenicity and safety of two
doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and
seronegative patients with autoimmune rheumatic diseases in Brazil: a
subgroup analysis of a phase 4 prospective study. The Lancet
Rheumatology 4 , e113-e124. 10.1016/s2665-9913(21)00327-1.
34. Oshiro, T.M., da Silva, L.T., Ortega, M.M., Perazzio, S.F., Duarte,
A., and Carneiro-Sampaio, M. (2022). Patient with agammaglobulinemia
produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine.
Clinics (Sao Paulo) 77 , 100007. 10.1016/j.clinsp.2022.100007.
35. Peng, Y., Felce, S.L., Dong, D., Penkava, F., Mentzer, A.J., Yao,
X., Liu, G., Yin, Z., Chen, J.L., Lu, Y., et al. (2022). An
immunodominant NP105-113-B*07:02 cytotoxic T cell response controls
viral replication and is associated with less severe COVID-19 disease.
Nat Immunol 23 , 50-61. 10.1038/s41590-021-01084-z.
36. Kundu, R., Narean, J.S., Wang, L., Fenn, J., Pillay, T., Fernandez,
N.D., Conibear, E., Koycheva, A., Davies, M., Tolosa-Wright, M., et al.
(2022). Cross-reactive memory T cells associate with protection against
SARS-CoV-2 infection in COVID-19 contacts. Nature Communications13 . 10.1038/s41467-021-27674-x.
37. Laffort, C., Deist, F.L., Favre, M., Caillat-Zucman, S.,
Radford-Weiss, I., Fraitag, S., Blanche, S., Cavazzana-Calvo, M.,
Basile, G.d.S., de Villartay, J.P., et al. (2004). Severe cutaneous
papillomavirus disease after haemopoietic stem-cell transplantation in
patients with severe combined immune deficiency caused by common γc
cytokine receptor subunit or JAK-3 deficiency. The Lancet 363 ,
2051-2054. 10.1016/s0140-6736(04)16457-x.
38. Nowak, K., Linzner, D., Thrasher, A.J., Lambert, P.F., Di, W.L., and
Burns, S.O. (2017). Absence of gamma-Chain in Keratinocytes Alters
Chemokine Secretion, Resulting in Reduced Immune Cell Recruitment. J
Invest Dermatol 137 , 2120-2130. 10.1016/j.jid.2017.05.024.
39. Lau, E.H.Y., Tsang, O.T.Y., Hui, D.S.C., Kwan, M.Y.W., Chan, W.H.,
Chiu, S.S., Ko, R.L.W., Chan, K.H., Cheng, S.M.S., Perera, R., et al.
(2021). Neutralizing antibody titres in SARS-CoV-2 infections. Nat
Commun 12 , 63. 10.1038/s41467-020-20247-4.
40. Sattler, A., Schrezenmeier, E., Weber, U.A., Potekhin, A., Bachmann,
F., Straub-Hohenbleicher, H., Budde, K., Storz, E., Pross, V., Bergmann,
Y., et al. (2021). Impaired humoral and cellular immunity after
SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney
transplant recipients. J Clin Invest 131 . 10.1172/JCI150175.
41. Mateus, J., Dan, J.M., Zhang, Z., Rydyznski Moderbacher, C.,
Lammers, M., Goodwin, B., Sette, A., Crotty, S., and Weiskopf, D.
(2021). Low-dose mRNA-1273 COVID-19 vaccine generates durable memory
enhanced by cross-reactive T cells. Science 374 , eabj9853.
10.1126/science.abj9853.